AR056471A1 - Formulaciones de acetato de bazedoxifeno - Google Patents
Formulaciones de acetato de bazedoxifenoInfo
- Publication number
- AR056471A1 AR056471A1 ARP060103666A ARP060103666A AR056471A1 AR 056471 A1 AR056471 A1 AR 056471A1 AR P060103666 A ARP060103666 A AR P060103666A AR P060103666 A ARP060103666 A AR P060103666A AR 056471 A1 AR056471 A1 AR 056471A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- pharmaceutical formulation
- constitutes
- composition according
- component
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente está dirigida a formulaciones de acetato de bazedodoxifeno que tienen una conversion polimorfica reducida, a composiciones que las contienen, a sus preparaciones y sus usos. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende una cantidad farmacéuticamente eficaz de acetato de bazedoxifeno y un sistema de vehículos o excipientes, donde el sistema de vehículos o excipientes comprende: a) un primer componente relleno/diluyente que constituye de alrededor de 5% a alrededor de 85% en peso de la formulacion farmacéutica; b) un segundo componente relleno/diluyente opcional que constituye de alrededor de 5% a alrededor de 85% en peso de la formulacion farmacéutica; c) un componente antioxidante opcional que constituye hasta alrededor de 15% en peso de la formulacion farmacéutica; d) un componente agente deslizante/desintegrante que constituye de alrededor de 0,01% a alrededor de 10% en peso de la formulacion farmacéutica; y e) un componente lubricante que constituye de alrededor de 0,01% a alrededor de 10% en peso de la formulacion farmacéutica. Reivindicacion 29: Una tableta caracterizada porque comprende una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 28. Reivindicacion 31: Una cápsula caracterizada porque contiene una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 28. Reivindicacion 32: Un proceso no acuoso para prepara una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 28, el proceso caracterizado porque comprende mezcla, directa, granulacion seca o compactacion por rodillos. Reivindicacion 38: Un producto caracterizado porque se fabrica por el proceso de cualquiera de las reivindicaciones 32 a 37.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71076105P | 2005-08-24 | 2005-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056471A1 true AR056471A1 (es) | 2007-10-10 |
Family
ID=37772333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103666A AR056471A1 (es) | 2005-08-24 | 2006-08-23 | Formulaciones de acetato de bazedoxifeno |
Country Status (21)
Country | Link |
---|---|
US (1) | US7771744B2 (es) |
EP (1) | EP1919456A2 (es) |
JP (2) | JP2009506053A (es) |
KR (2) | KR101584674B1 (es) |
CN (1) | CN101304731B (es) |
AR (1) | AR056471A1 (es) |
AU (1) | AU2006283121A1 (es) |
BR (1) | BRPI0615341A2 (es) |
CA (1) | CA2620174A1 (es) |
CR (1) | CR9746A (es) |
EC (1) | ECSP088214A (es) |
GT (1) | GT200600383A (es) |
IL (2) | IL189648A (es) |
MX (1) | MX2008002484A (es) |
NO (1) | NO20080991L (es) |
PE (1) | PE20070425A1 (es) |
RU (1) | RU2417084C2 (es) |
SV (1) | SV2008002825A (es) |
TW (1) | TW200738281A (es) |
WO (1) | WO2007024961A2 (es) |
ZA (1) | ZA200801742B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06011685A (es) * | 2004-04-08 | 2006-12-14 | Wyeth Corp | Formulaciones de dispersiones solidas de acetato de bazedoxifeno. |
AU2006283121A1 (en) * | 2005-08-24 | 2007-03-01 | Wyeth | Bazedoxifene acetate formulations and manufacturing process thereof |
AU2007232098A1 (en) * | 2006-03-31 | 2007-10-11 | Rubicon Research Private Limited | Directly compressible composite for orally disintegrating tablets |
WO2008079342A2 (en) * | 2006-12-21 | 2008-07-03 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets |
US20100016582A1 (en) * | 2008-02-11 | 2010-01-21 | Wyeth | Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate |
ITMI20091109A1 (it) | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
CA2818068C (en) * | 2010-11-30 | 2019-06-11 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
EP2471770A1 (en) * | 2010-12-28 | 2012-07-04 | Sandoz Ag | Method of preparing polymorphic pure form A of bazedoxifene acetate |
WO2013182170A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
WO2013182169A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate |
CN103877581B (zh) * | 2014-03-24 | 2016-03-02 | 江苏知原药业有限公司 | 一种性能优异的乙酸巴多昔芬缓释制剂 |
WO2018182205A1 (ko) * | 2017-03-30 | 2018-10-04 | 한미약품 주식회사 | 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물 |
KR101940569B1 (ko) * | 2017-05-24 | 2019-01-21 | 아주대학교산학협력단 | 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 |
CN112076163B (zh) * | 2019-06-14 | 2023-06-20 | 四川科伦药物研究院有限公司 | 一种醋酸巴多昔芬片的药物组合物及其制备方法 |
CN111004165A (zh) * | 2019-12-03 | 2020-04-14 | 南京正济医药研究有限公司 | 一种醋酸巴多昔芬晶型a的制备方法 |
CN112754999A (zh) * | 2021-01-23 | 2021-05-07 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法 |
CN113368075A (zh) * | 2021-06-29 | 2021-09-10 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬片及其制备方法 |
CA3229700A1 (en) * | 2021-08-23 | 2023-03-02 | Jan Brabek | Treatment of covid-19 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686094A (en) * | 1991-04-01 | 1997-11-11 | Theratech, Inc. | Controlled release formulations for the treatment of xerostomia |
CN1119998C (zh) * | 1995-06-22 | 2003-09-03 | 阿克佐诺贝尔公司 | 去氧孕烯的压制干颗粒片 |
US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
CN1658868A (zh) * | 2002-06-13 | 2005-08-24 | 惠氏公司 | 巴泽昔芬治疗方案 |
RU2006123939A (ru) | 2004-01-13 | 2008-02-20 | Вайет (Us) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы |
JP2007532548A (ja) | 2004-04-07 | 2007-11-15 | ワイス | バゼドキシフェンアセテートの結晶質多形体 |
SG151331A1 (en) | 2004-04-07 | 2009-04-30 | Wyeth Corp | Crystalline polymorph of a bazedoxifene acetate |
CN1938272A (zh) * | 2004-04-07 | 2007-03-28 | 惠氏公司 | 巴泽多昔芬醋酸盐的结晶多晶型物 |
MXPA06011685A (es) * | 2004-04-08 | 2006-12-14 | Wyeth Corp | Formulaciones de dispersiones solidas de acetato de bazedoxifeno. |
AU2006283121A1 (en) * | 2005-08-24 | 2007-03-01 | Wyeth | Bazedoxifene acetate formulations and manufacturing process thereof |
-
2006
- 2006-08-23 AU AU2006283121A patent/AU2006283121A1/en not_active Abandoned
- 2006-08-23 CA CA002620174A patent/CA2620174A1/en not_active Abandoned
- 2006-08-23 MX MX2008002484A patent/MX2008002484A/es active IP Right Grant
- 2006-08-23 JP JP2008528116A patent/JP2009506053A/ja not_active Withdrawn
- 2006-08-23 CN CN2006800394740A patent/CN101304731B/zh not_active Expired - Fee Related
- 2006-08-23 AR ARP060103666A patent/AR056471A1/es not_active Application Discontinuation
- 2006-08-23 KR KR1020087006992A patent/KR101584674B1/ko active IP Right Grant
- 2006-08-23 PE PE2006001025A patent/PE20070425A1/es not_active Application Discontinuation
- 2006-08-23 WO PCT/US2006/032935 patent/WO2007024961A2/en active Application Filing
- 2006-08-23 KR KR1020147017847A patent/KR20140088917A/ko not_active Application Discontinuation
- 2006-08-23 TW TW095130979A patent/TW200738281A/zh unknown
- 2006-08-23 BR BRPI0615341-0A patent/BRPI0615341A2/pt not_active Application Discontinuation
- 2006-08-23 RU RU2008107580/15A patent/RU2417084C2/ru active
- 2006-08-23 GT GT200600383A patent/GT200600383A/es unknown
- 2006-08-23 US US11/508,801 patent/US7771744B2/en active Active
- 2006-08-23 EP EP06802170A patent/EP1919456A2/en not_active Withdrawn
-
2008
- 2008-02-19 CR CR9746A patent/CR9746A/es not_active Application Discontinuation
- 2008-02-21 IL IL189648A patent/IL189648A/en active IP Right Grant
- 2008-02-22 EC EC2008008214A patent/ECSP088214A/es unknown
- 2008-02-22 SV SV2008002825A patent/SV2008002825A/es not_active Application Discontinuation
- 2008-02-22 ZA ZA200801742A patent/ZA200801742B/xx unknown
- 2008-02-27 NO NO20080991A patent/NO20080991L/no not_active Application Discontinuation
-
2013
- 2013-06-11 JP JP2013122658A patent/JP2013209419A/ja active Pending
-
2014
- 2014-06-26 IL IL233392A patent/IL233392A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2008002484A (es) | 2008-04-07 |
IL189648A0 (en) | 2008-08-07 |
KR20080043853A (ko) | 2008-05-19 |
IL189648A (en) | 2014-07-31 |
JP2009506053A (ja) | 2009-02-12 |
US20070048374A1 (en) | 2007-03-01 |
AU2006283121A1 (en) | 2007-03-01 |
WO2007024961A2 (en) | 2007-03-01 |
US7771744B2 (en) | 2010-08-10 |
NO20080991L (no) | 2008-05-15 |
JP2013209419A (ja) | 2013-10-10 |
CN101304731A (zh) | 2008-11-12 |
CA2620174A1 (en) | 2007-03-01 |
GT200600383A (es) | 2007-03-29 |
TW200738281A (en) | 2007-10-16 |
KR20140088917A (ko) | 2014-07-11 |
BRPI0615341A2 (pt) | 2011-05-17 |
ZA200801742B (en) | 2010-10-27 |
CN101304731B (zh) | 2012-06-20 |
SV2008002825A (es) | 2008-06-30 |
EP1919456A2 (en) | 2008-05-14 |
CR9746A (es) | 2008-08-21 |
KR101584674B1 (ko) | 2016-01-13 |
IL233392A (en) | 2017-02-28 |
WO2007024961A3 (en) | 2007-06-28 |
IL233392A0 (en) | 2014-08-31 |
RU2008107580A (ru) | 2009-09-27 |
RU2417084C2 (ru) | 2011-04-27 |
PE20070425A1 (es) | 2007-07-02 |
ECSP088214A (es) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056471A1 (es) | Formulaciones de acetato de bazedoxifeno | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
EP3916091A3 (en) | Dry powder composition comprising long-chain rna | |
SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
EA201001852A1 (ru) | Твердые фармацевтические составы, содержащие bibw 2992 | |
CL2011000653A1 (es) | Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer. | |
CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
BRPI0608877B8 (pt) | composição imunogênica de rotavírus líquida, uso de um antígeno de rotavírus, um açúcar e um carboxilato, e, método para a preparação de uma composição de rotavírus líquida | |
MX2008009357A (es) | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion. | |
GT201200024A (es) | Formulación subcutánea de anticuerpo anti-her2 | |
WO2012075081A3 (en) | High-strength testosterone undecanoate compositions | |
BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
CA2716874A1 (en) | A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases | |
GT201000095A (es) | Producto de dispersión sólida que contiene un compuesto a base de n-aril urea | |
WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
TW200640502A (en) | Tablets with improved drug substance dispersibility | |
WO2015104292A3 (en) | Compounds for use in treating or preventing cancerous diseases | |
MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
PH12015502556A1 (en) | Modified release formulation | |
BRPI0518789A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete | |
NZ594035A (en) | Solid oral formulations of a pyridopyrimidinone | |
MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. | |
MX2020005117A (es) | Formulaciones peptídicas de liberación sostenida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |